▟ Vinebot intrinsic value, daily

← back

INCY Incyte

pharma · valued with opus medium conviction · deep-dived 2026-11-16

STRONG BUY
Intrinsic value$108.52
Price (at call)$120.97
Margin of safety -10.3%
vs market (rating basis) +42.7%

Mid-teens growth and net cash roughly cover the Jakafi cliff; fairly priced unless mutCALR delivers.

The story

Incyte is a net-cash, R&D-heavy biotech whose cash engine is Jakafi (ruxolitinib), which loses US exclusivity around 2028. It is diversifying through Opzelura, Niktimvo, Monjuvi and a mutant-CALR/JAK2V617F pipeline. TTM revenue of about $6.0B shows the commercial base is still growing at mid-teens. The life-cycle question is whether newer franchises can fill the Jakafi cliff before margins compress.

I kept all previous drivers because the facts confirm the story rather than change it. TTM revenue is up about 17% versus FY, and the 13.3% TTM margin reflects lumpy in-licensing and IPR&D charges, not lost economics; normalized margins have run around 30%. The 8-year horizon and 31% target margin still price in a Jakafi erosion that partly offsets pipeline growth, and the net cash of $3.1B adds about $15 per share.

Value drivers

Revenue growth (Y1)12.0%
Terminal growth2.0%
Forecast horizon8y
Target operating margin31.0%
Years to target margin5
Sales-to-capital1.13
Beta1.05
Failure probability2.0%
Cost of capital (WACC)9.9%
Terminal WACC9.7%

Valuation bridge

PV of explicit FCFF6.60B
PV of terminal value12.87B
Equity value22.12B
÷ shares → per share$108.52

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 6.73B 12.0% 16.8% 875.74M 638.31M 237.43M 216.08M
2 7.44B 10.6% 20.4% 1.17B 629.80M 542.38M 449.24M
3 8.12B 9.1% 23.9% 1.50B 602.27M 899.58M 678.11M
4 8.75B 7.7% 27.5% 1.86B 554.63M 1.30B 893.73M
5 9.30B 6.3% 31.0% 2.23B 486.78M 1.74B 1.09B
6 9.75B 4.9% 31.0% 2.34B 399.79M 1.94B 1.10B
7 10.09B 3.4% 31.0% 2.42B 295.91M 2.12B 1.10B
8 10.29B 2.0% 31.0% 2.47B 178.54M 2.29B 1.08B

Key risks

  • Jakafi generic erosion from 2028 is steeper than Opzelura/Niktimvo growth can offset
  • mutCALR antibody and JAK2V617F programs fail or slip, leaving no second franchise
  • Continued expensive BD and IPR&D charges that permanently depress margins and destroy capital

Catalysts

  • Proof-of-concept and registrational data for the mutCALR antibody (INCA033989) in MPNs
  • Opzelura label expansions (pediatric AD, HS, prurigo) and Jakafi XR lifecycle extension

History

DatePriceIntrinsicMoSRating
2026-11-16$120.97 $108.52 -10.3% STRONG BUY
2026-10-13$111.36 $116.94 +5.0% STRONG BUY
2026-09-09$124.40 $120.46 -3.2% STRONG BUY
2026-08-07$118.38 $122.18 +3.2% STRONG BUY
2026-07-06$116.86 $106.99 -8.4% STRONG BUY
2026-06-23$104.40 $107.80 +3.3% STRONG BUY